15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS

Trial Profile

15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Grapiprant (Primary) ; Gemcitabine
  • Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
    • 19 May 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 19 May 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top